Reports from Krause Analytical rest on a converging set of public signals that, taken together, clear the evidence threshold for a Substantiated rating.
Signals Supporting the Rating
The laboratory is operated under a named principal, Mark Krause, whose identity is independently corroborated by a public LinkedIn profile. The domain krauselabs.com has been registered since December 2021, giving the operation a multi-year online footprint.
Krause Analytical publishes a dedicated peptide-testing page listing over 30 specific compounds - including BPC-157, TB-500, semaglutide, and tirzepatide - with routine analysis for purity, potency, and identity. The lab discloses concrete instrumentation: HPLC-UV and HPLC-MS.
A verification portal is offered on the lab's website, though the directory could not confirm a real report through it, so the portal counts as an offered service, not as proven functionality. The lab states it accepts private orders from individuals alongside industry and legal clients.
Neutral Signals (Not Treated as Concerns)
Several neutral signals are present and are not treated as concerns:
- No business-register entry was found, which is normal for a small private lab.
- No verifiable accreditation-body entry could be located despite an ISO/IEC 17025 claim, meaning the claim remains neither confirmed nor refuted.
- No public pricing is displayed.
Minor Inconsistency
One minor inconsistency was noted: a source labels the lab's address as a PO Box while a Certificate of Analysis lists the same address as the laboratory address. This discrepancy is minor and does not disqualify the lab.
Conclusion
No concrete open concern rises to a Watch-level issue. These are signals, not a verdict.